Influenza Vaccine Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The influenza vaccine market was valued at USD 6.79 Billion in 2025. It is poised to grow at a CAGR of 7.30% during the forecast period of 2026-2035, and reach USD 13.74 Billion by 2035. The market growth is driven by the rising influenza incidence, expanding immunization programs, increasing elderly population, and continuous advancements in vaccine technologies globally.

Key Market Trends and Insights

• By form, the inactivated segment accounted for approximately 90% of the market share in the historical period and is likely to dominate the market.
• By age group, adults represented over 64% of the market size in the historical period and are likely to remain the dominant segment.
• By country, the United States accounted for around 47% of the market share in the historical period and is likely to maintain its dominance.

Market Size and Forecast

• Market Size (2025): USD 6.79 Billion
• Projected Market Size (2035): USD 13.74 Billion
• CAGR (2026-2035): 7.30%

Influenza Vaccine Market Overview

The market is driven by seasonal disease burden, government immunization programs, and rising awareness of preventive healthcare. Increasing elderly populations and high-risk groups support steady demand. Technological advancements, including cell-based and recombinant vaccines, enhance efficacy and production speed. Strong public-private partnerships and global vaccination initiatives continue to expand coverage, ensuring consistent market growth across developed and emerging regions. The market reached a value of approximately USD 6.79 Billion in 2025.

Influenza Vaccine Market Growth Drivers

Global Influenza Burden Driving the Market Demand

Rising infectious disease prevalence and increasing hospitalization rates are key factors supporting vaccine uptake globally. For instance, in February 2025, the World Health Organization reported approximately one billion influenza cases annually, including 3-5 million severe cases and up to 650,000 deaths worldwide. This substantial disease burden is expected to drive the disease prevalence by accelerating immunization demand and strengthening preventive healthcare strategies globally.

Influenza Vaccine Market Trends

Key trends shaping the market include rising vaccination coverage, increasing adoption of advanced technologies, expanding government programs, and growing awareness of preventive healthcare globally.

Advanced Vaccine Innovation Boosting the Influenza Market Expansion

Rising influenza burden and increasing demand for next-generation immunization technologies are key growth enablers. For instance, in April 2026, Moderna initiated a Phase III trial for its mRNA-based pandemic influenza vaccine. Additionally, regulatory approvals for combination vaccines are accelerating adoption. These developments are expected to strengthen the technological advancement by enhancing vaccine efficiency and broadening immunization strategies globally.

Influenza Vaccine Market Segmentation

Market Breakup by Form

• Inactivated
• Live Attenuated
• Recombinant
• Others

Market Breakup by Age Group

• Pediatric
• Adults
• Geriatric

Market Breakup by Route of Administration

• Nasal Spray
• Injection

Market Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Channel
• Government and Institutional Supply Programs

Market Breakup by End User

• Hospital and Clinics
• Homecare Settings
• Others

Market Breakup by Country

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan
• India

Influenza Vaccine Market Share

Inactivated Expected to Lead the Market Segment by Form

The inactivated segment accounted for approximately 90% of the market size in the historical period, reflecting strong clinical adoption and a well-established safety profile. Widespread use in national immunization programs further supports its position. The segment is likely to dominate due to consistent demand patterns and scalable production capabilities, reinforcing overall vaccine adoption across global healthcare systems and public health initiatives.

Influenza Vaccine Market Analysis by Region

The United States accounted for around 47% of the market share in the historical period, supported by robust vaccination coverage and strong government initiatives. Advanced healthcare infrastructure and high public awareness sustain demand levels. The country is likely to maintain its dominance due to continued investments and widespread seasonal uptake, strengthening overall immunizationcoverage across diverse population groups.

Leading Players in the Influenza Vaccine Market

The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Sanofi SA

Founded in 1973 and headquartered in Paris, France, Sanofi SA is a global leader in vaccines through Sanofi Pasteur. Its influenza portfolio includes Fluzone and Vaxigrip, widely used worldwide. The company continues expanding manufacturing and innovation, strengthening the influenza vaccine market through strong global distribution and advanced immunization technologies.

GlaxoSmithKline plc

Established in 2000 and headquartered in Brentford, United Kingdom, GlaxoSmithKline plc is a major vaccine manufacturer. Its influenza portfolio includes Fluarix and Flulaval. Through subsidiary GSK Vaccines, it emphasizes innovation in adjuvanted vaccines, contributing significantly to the market by enhancing immune response and targeting vulnerable populations globally.

CSL Seqirus

Founded in 2015 and headquartered in Maidenhead, United Kingdom, CSL Seqirus specializes in influenza vaccines under CSL Limited. Its portfolio includes Fluad, Flucelvax, and Afluria. The company focuses on cell-based and adjuvanted technologies, ensuring reliable seasonal supply and strengthening pandemic preparedness through advanced vaccine manufacturing capabilities worldwide.

AstraZeneca plc

Established in 1999 and headquartered in Cambridge, United Kingdom, AstraZeneca plc focuses on biopharmaceutical innovation. While not a major influenza vaccine producer, it contributes through research collaborations and respiratory therapies. Its broader portfolio supports immunization strategies and pandemic preparedness initiatives, enhancing global healthcare response capabilities against infectious respiratory diseases.

Other key players in the market are Pfizer Inc., Merck & Co. Inc., Moderna Inc., Novavax Inc., Bharat Biotech, and Serum Institute of India.

Key Questions Answered in the Influenza Vaccine Market Report

• What was the influenza vaccine market value in 2025?
• What is the influenza vaccine market forecast outlook for 2026-2035?
• What major factors aid the demand for the influenza vaccine market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major influenza vaccine market trends?
• Which form is expected to dominate the market segment?
• Which age group is expected to dominate the market segment?
• Which route of administration is expected to dominate the market segment?
• Which distribution channel is expected to dominate the market segment?
• Which end user is expected to dominate the market segment?
• Who are the key players in the influenza vaccine market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?